CART T Elicits Strong Response for Multiple Myeloma
Dec. 9, 2020 — For patients with heavily-pretreated multiple myeloma, the strong responses seen with the new (CAR T-cell treatment ciltacabtagene autoleucel (cilta-cel) have also been prolonged, according to investigators in the CARTITUDE-1 trial. Among 97 patients with multiple myeloma whose cancer got worse while on three or more prior types of treatment or … Read more